The drugmaker said on Thursday that the experimental product, MEDI2452, was in pre-clinical tests at its MedImmune biotech unit.
There are currently no approved medicines to counteract the blood-thinning effects of drugs such as Brilinta, which work by blocking the action of platelets in the blood.